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Abstract: 
 
Objective: To estimate the treatment effect from participating in an asthma intervention that was part of 
the National Asthma Control Program. 
Study Setting: Data on children who participated in asthma case management (N=270) and eligible 
children who did not participate in case management (N=2,742) were extracted from a claims database. 
Study Design: We created 81 measures of health care utilization and 40 measures of neighborhood 
characteristics that could be related to participation in the program. The participation model was selected 
using the cross-validation-based Deletion Substitution and Addition (DSA) algorithm. We used optimal 
full matching for the vector of Mahalanobis’ distances and propensity scores to estimate the difference 
between participants and non-participants in the probability of a range of asthma outcomes. 
Principal Findings: Compared to non-participants, participants were more likely to have vaccinations for 
pulmonary illness, use controller medications, and have a refill for rescue medication. There was no 
statistically significant difference in the number of nebulizer treatments or ED visits between the two 
groups. We find that the asthma program had no significant effect on overall asthma control. 
Conclusion: We are not able to discern whether the lack of an effect in overall control is due to the 
effectiveness of the program, heterogeneity of effects or barriers outside the program’s control. We 
discuss how current programs could be modified to better inform future research and program design. 
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 Estimation of Treatment Effect of Asthma Case Management 
Using Propensity Score Methods 
 
 
 
 
 
 
Objective: To estimate the treatment effect from participating in an asthma intervention that was 
part of the National Asthma Control Program. 
 
Study Setting: Data on children who participated in asthma case management (N=270) and 
eligible children who did not participate in case management (N=2,742) were extracted from a 
claims database. 
 
Study Design: We created 81 measures of health care utilization and 40 measures of 
neighborhood characteristics that could be related to participation in the program. The 
participation model was selected using the cross-validation-based Deletion Substitution and 
Addition (DSA) algorithm. We used optimal full matching for the vector of Mahalanobis’ 
distances and propensity scores to estimate the difference between participants and non-
participants in the probability of a range of asthma outcomes. 
 
Principal Findings: Compared to non-participants, participants were more likely to have 
vaccinations for pulmonary illness, use controller medications, and have a refill for rescue 
medication. There was no statistically significant difference in the number of nebulizer 
treatments or ED visits between the two groups. We find that the asthma program had no 
significant effect on overall asthma control 
 
Conclusion: We are not able to discern whether the lack of an effect in overall control is due to 
the effectiveness of the program, heterogeneity of effects or barriers outside the program’s 
control. We discuss how current programs could be modified to better inform future research and 
program design. 
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1. Introduction 
The most prominent example of public investment in asthma programs is the CDC’s 
National Asthma Control Program. Created in 1999, the program has spent almost $208 million 
(CDC, 2007)1 on two intervention models - the Inner-City Asthma Intervention and the 
Controlling Asthma in American Cities Project (CAACP).2 Each model attempts to achieve 
clinical-like results in a community setting similar to that of the National Cooperative Inner-City 
Asthma Study (NCICAS). NCICAS was a family-focused program targeted at inner-city children 
with moderate to severe asthma that included over one-thousand families randomized into 
intervention and control groups. A master's-level asthma educator met with caregivers and 
children in a combination of group classes and individualized meetings. The NCICAS 
intervention was publicized as "a scientifically proven asthma intervention program" (NIH, 
2001), despite the fact that the assessment of the program found no statistically significant 
differences in utilization of health care between the intervention and control groups. While there 
was a statistically significant difference between the intervention and control groups in the 
maximum number of symptom days3
During the design and implementation of the National Asthma Control Program, there 
was little attention paid to assessing the effectiveness of the interventions that were funded. 
While some programs have summarized process outcomes and qualitative assessments (for a 
 in year one of the study, after two years, differences were 
no longer significant. 
                                                 
1 In 2003, the CDC spending on asthma programs ($36.9 million) was greater than for autism ($10.8 million) but 
less than from diabetes ($63 million) or lead prevention programs ($42.0 million). The projects funded in 2003 
included 7 tracking programs, 49 interventions and 39 community partnerships. For more information see 
http://www.cdc.gov/asthma/aag07.htm#more. 
2 The Inner-City Asthma Intervention was located in 23 sites. The programs all had asthma educators who were 
based in health organizations that treated low-income inner-city children. Controlling Asthma in American Cities 
Project (CAACP) was also based in low-income urban areas, but each intervention was locally developed and varied 
in the design and components. CAACP was implemented in seven cities.  
3 The number of days with asthma symptoms over a two-week period averaged over six observations during the 
year. 
 review see the 2006 supplement to Annals of Allergy, Asthma and Immunology), there are few 
data on actual health outcomes and, therefore, no rigorous evaluation of these investments to 
determine if they are, in fact, the best use of available funds to reduce morbidity in childhood 
asthma. At present, whether these interventions in urban communities can shift behavior from 
treatment of asthma attacks to prevention of attacks through risk-reducing investments, and 
whether costs can be reduced and quality of life can be improved, remains an open question.   
In this paper, we examine Oakland Kicks Asthma (OKA), a case management program 
that is part of the CAACP.  Oakland, CA is among the most diverse cities in the United States, 
with 29% of children living in poverty (U.S. Census, 2006). The annual rate of asthma-related 
hospitalizations for children ages 0-14 is approximately twice that for the state (36.63 versus 
18.73 per 10,000 residents/year).4 The Oakland Kicks Asthma (OKA) case management program 
was jointly developed by the American Lung Association of the East Bay and researchers at the 
UC Berkeley School of Public Health.5
 
 Children were referred by physicians, the local Medicaid 
provider or identified by surveillance surveys administered in the middle and high schools of the 
Oakland Unified School District. Over three to five months, an asthma case manager visited each 
participating household 3-4 times to develop an asthma management plan and assist with its 
implementation. The program was free to all families. 
                                                 
4 The 95% confidence intervals are (34.59 to 38.72) versus (18.22 to 19.04) per 10,000 residents (Stockman et al., 
2003). 
5 The asthma program, data collection tools and all protocols for protection of personal data were approved by the 
Committee for the Protection of Human Subjects, UC, Berkeley. 
 2. Methods 
Matching Participants and Non-participants 
To determine the real effectiveness of the program, it is necessary to compare those 
outcomes to the outcomes realized by a comparison group that did not participate in the program. 
This is a non-trivial problem, because households do not randomly sort themselves into 
otherwise-identical treatment and control groups. Failure to correct, as completely as possible, 
for this non-random sorting will produce biased estimates of the treatment effect and a biased 
assessment of the program. We address this issue by matching participants to non-participants 
using the estimated propensity score.6
For each child who is eligible to participate in OKA, there are two possible decisions, 
participation and non- participation, denoted Ti=1 and Ti=0. Individuals differ on pre-
intervention characteristics that are associated with participation (xi). The pre-intervention 
variables fall into three different domains: health care use (e.g., count of pre-treatment ED 
visits), socio-demographics (e.g., race), and provider and plan data (e.g., AAH health care plan 
type). These domains are denoted 
   
, ,i i iu s p . The propensity score can be written as: 
( ) ( )| , ,i i i i i ie x pr T X u s p≡ =  
One caveat of propensity scores is that results may be sensitive to misspecification of the 
selection equation, especially in cases where there are quadratic terms (Drake, 1993). The 
economics and public health literature provides little guidance to construct our participation 
equation; thus, we rely on the cross-validation-based Deletion Substitution and Addition (DSA) 
algorithm to select a participation model. The DSA is a data-adaptive selection procedure based 
on cross-validation that relies on deletion, substitution, and addition moves to search through a 
                                                 
6 A cornerstone in evaluation methodology across disciplines is the seminal work by Rosenbaum and Rubin (1983, 
1985).  
 large space of possible polynomial models (Moore et al., 2008). The criterion for model 
selection is minimization of a loss function (empirical and cross-validated residual sum of 
squares) rather than tests of significance of parameters. The result is a vector of pre-treatment 
variables that includes interactions and polynomials x X∈ . The DSA procedure is publicly 
available as an R package at http://www.stat.berkeley.edu/~laan/Software/.  After using the DSA 
algorithm to select the model that best predicts the empirical distribution of participation, 
conditional on pre-treatment variables, propensity scores are calculated by logistic regression of 
participation on the selected vector ix . 
We use the most flexible method to match participants to non-participants on propensity 
scores, optimal full matching for the vector of Mahalanobis’ distances and propensity scores 
(Haviland et al., 2007 and Hansen and Klopfer, 2006).7 and 8
ix
 Full matching improves our 
statistical power over pair matching or any other subset matching (Rosenbaum, 1989), which is 
critical in our case where we have a limited number of observations on participants but a 
substantially larger number of non-participants. This matching proceeds in two steps. First, the 
Mahalanobis distances are defined as the difference between the vectors of pre-treatment 
variables that includes the logit of the propensity score for each participant ( ) and non-
participant ( jx ) pair, weighted by the inverse of the covariance matrix of the pre-treatment 
variables and the logit of the propensity score, C: 
                                                 
7 There are several options for using the score to create comparison groups; see D'Agostino (1998) for a summary of 
three approaches. While pair matching has a long history in the literature, full matching was introduced relatively 
later (Rosenbaum, 1991). 
8 The advantage of using the Mahalanobis distance is that it takes into account the covariance among the variables in 
calculation of distances; however, binary elements that are rare can overly influence matching based on 
Mahalanobis distances (Rosenbaum and Rubin, 1983). Inclusion of the propensity score in the vector of covariates 
can reduce bias in these situations essentially by balancing some deviations between individual covariates with 
closer matches on the composite of those covariates as reflected in the propensity score (Rubin and Thomas, 2000). 
Given that we know outcomes such as hospitalizations are rare, we include the propensity score in the vector of pre-
treatment variables. 
  
( ) ( )1,i j i j i jd x x C x x
Τ −≡ − −    . 
 
The differences or “distance” matrix, D, is formed with participants as rows and non-participants 
as columns and the Mahalanobis distance for each pair in the appropriate cell. In any case where 
the difference in propensity score between participant and non-participant is greater than 0.25 of 
the standard deviation of the logit of the observed propensity scores, we assign a penalty of 500 
units9
In the second step, once the matrix D is constructed, optimal full matching uses an 
algorithm based on a minimum-cost network flow to create k to m matches of participants and 
non-participants. Essentially, the matching creates sets based on the values in the matrix D, and 
allows for a set to contain any number of participants or controls. The optimal match algorithm 
considers the group costs associated with a particular matched set. For instance, a match might 
be made on the second- or third-closest distance rather than the first because another set would 
be worse off if the closest match were made.  
 to prevent matching.  
 
Comparison of Health Outcomes 
We use health care encounters as markers of asthma exacerbations (undesirable health 
care encounters) and of managed or controlled asthma (appropriate health care encounters). First, 
we estimate the mean effect of participation on the probabilities of two binary measures of 
preventative health care and three binary measures of treatment of asthma exacerbations. In these 
five binary measures we account for the matching of participants to non-participants, using a 
                                                 
9 This penalty serves the same function as a caliper (Haviland et al., 2007) where the standard caliper is a quarter of 
a standard deviation of the differences in estimated propensity scores (Rosenbaum and Rubin, 1985). 
 conditional logistic regression to measure the effect of participation in the program within a 
matched group. However, individual measures of health care utilization give an incomplete 
picture of a child's overall asthma status; ideally, we would compare the evolution of health 
status between participants and non-participants. To do this, we create an indicator that captures 
the transition between normal and negative asthma states over time, and evaluate the effect of 
program participation on this indicator (H=1,2,3,4). We used Proc GLIMMIX to implement 
conditional logistic regression for this multinomial outcome.  Matched sets were treated as 
random intercepts.  The reference group was subjects who had stable outcomes before and after 
the intervention. This indicator is discussed in more detail below. 
 
3. Study Data 
Our data come from the claims database of Alameda Alliance for Health (AAH), a not-
for-profit Medicaid umbrella organization that manages and provides health care services for 
low-income families in Alameda County. To construct our sample of participants and non-
participants (controls), we examined all AAH plan members who had a health claim with a 
primary diagnosis code for asthma (ICD-9 of 493.x) and were between the ages of 6 and 20 at 
the time of service. We divided this set of children into those who had a record of participation in 
OKA (n=282) and non-participation (n=8,307). Figure I describes the criteria for inclusion in 
either the treatment or comparison group, and how many individuals were excluded at each step. 
We randomly assigned each potential control a "start date" based on the actual distribution of 
program start dates of participants (see Johnson et al., 2005)10
                                                 
10 For instance, if 10 out of 270 children (4%) started OKA in February 2005, we randomly assigned 110 out of 
2,742 potential controls (4%) the same start date. 
 to create comparable pre-treatment 
 and post-treatment periods. Because asthma symptoms often show seasonal patterns (Gergen et 
al., 2002), we consider outcomes at six-months and twelve-months after the intervention.  
<<Insert Figure I here>> 
Ideally, we would have complete symptom information on participants and non-
participants. In the absence of these data for non-participants, we created an inventory of health 
care utilization measures based on the billing codes for asthma-relevant health service encounters 
(summarized in Table A.1 in the appendix) that was as comprehensive as possible. With the 
exception of home medical equipment, allergy testing, allergy immunology, and participation in 
an asthma program other than OKA, variables were defined as both a binary measure (0=no 
encounter, 1=any encounter) and a count of encounters. In addition to health care encounters, we 
identified asthma-related prescription drug claims and distinguished between rescue medications 
(for use in asthma exacerbation) and controller medications (preventative medication). An 
important marker of a significant asthma exacerbation in children is the use of systemic/oral 
glucocorticoids (e.g., Prednisone), although these are not limited to asthma treatment; a 
prescription for glucocorticoids was included in the measure of steroid use only if it was in 
conjunction with a health care encounter with an asthma diagnosis. As with health care 
utilization, for each class of medication (rescue, control, systemic steroid), we created both 
binary and count variables. In addition, we created indicators of excessive or adequate use based 
on recommended doses and prescription volumes.11  Lastly, we created a medication intensity 
scale following Schatz et al (2006).12
                                                 
11 Information on doses per canister was compiled using a Medline search on each prescription inhaler. 
Documentation available from authors by request.  
 The result is a set of 72 measures of utilization and 
prescription use prior to participation in OKA.  
12 To create medication intensity scale, we ran a stepwise logistic regression of number of prescriptions on an 
indicator for a visit to the emergency department for asthma. Cut-points in the number of prescriptions were defined 
 To evaluate an individual's interaction with health providers, we reviewed the primary 
care provider (PCP) and specialty codes for all asthma-related claims. To assess continuity of 
care, we created counts of the total number of different primary care providers for all asthma 
claims within six and twelve months prior to the program start date, as well as an indicator 
variable for no PCP assigned. We also created counts of encounters with each of three types of 
providers (pulmonologist, allergist, or any respiratory specialist). Lastly, we created an indicator 
for whether the child had ever had a claim with an allergy diagnosis.  This set of individual 
characteristics included a total of nine variables.  
The eligibility files for AAH members provided socio-demographic data that included 
race/ethnicity, language, age, type of health plan and group, number of others included in the 
health plan, and number of adults on the health plan. To account for measurement bias 
introduced by gaps in service, we created a marker for those children who had gaps that totaled 
more than 65 days in the year prior to or after the program start date.  Twenty-eight children in 
the treatment group (10%) and 252 children in the potential control group (9%) had gaps in 
insurance coverage. We accounted for the potentially missing data that a gap in service might 
incur by inclusion of this variable in selection of the participation model using the DSA. There 
were eleven socio-demographic measures in total.13
Finally, to include community level variables, we geocoded our study subjects to the 
2000 US Census tract level to describe each child's neighborhood composition.  We considered 
forty measures that covered age distribution, country of birth, family structure (e.g., percentage 
married), employment status, and income characteristics of the neighborhood. 
  
                                                                                                                                                             
by breaks in the odds ratio for ED visit (see Appendix C for regression results). This approach to defining 
medication intensity has been found to be predictive of future utilization. 
13 A complete list of the procedure and billing codes used to create each variable is available from the authors upon 
request. 
 In Table I, we describe the basic socioeconomic characteristics of the treatment and non-
participant groups. Compared to the potential control group, the treatment group had slightly 
more Hispanic participants (and more Spanish speakers) and slightly fewer Black and Asian 
participants. This difference is perhaps due to recruiting efforts in a local clinic targeting 
Spanish-speaking families. The only other notable difference is that a substantially higher 
proportion of participants had an allergy diagnosis than non-participants. The small difference in 
the age distribution is explained by the program eligibility requirements. 
<<Insert Table I here>> 
As shown in Table II, the participant and non-participant groups differed in patterns of 
health care utilization. Relative to eligible AAH members who had an asthma diagnosis, OKA 
participants were more likely to have had an ED visit, outpatient visits, or a prescription for 
systemic steroids.  A higher proportion of participants fell into the high medication intensity 
categories for both rescue and controller medications. Participants were somewhat more likely to 
have had an inpatient hospitalization. Interestingly, participants also were more likely to have 
had preventative care such as flu or pneumonia vaccines or pulmonary testing. As a group, 
participants appear to be heavier users of health care than non-participants.  
<<Insert Table II here>> 
4. Construction of the Comparison Group 
The first step in constructing the comparison between program participants and non-
participants is to estimate the propensity scores (propensity to participate in the program) of all 
individuals based on pre-treatment characteristics. The complete vector of all measures of pre-
treatment characteristics consisted of 132 elements. We used the DSA to identify the most 
informative variables in each domain: health care use, socio-demographics, provider and plan 
 characteristics and neighborhood composition. We allowed for up to fifteen terms with a 
maximum of three interactions and a maximum power of three for each model. First we ran the 
DSA separately for each domain of explanatory variables. Next we created a subset of 
explanatory variables that were in any of the models that minimized the loss function four or 
more times out of all the runs of the data (we used 5 splits of the data for each of the 10 seeds). 
Finally we ran the DSA on this subset of variables. The result is a model for program 
participation based on a subset of pre-treatment characteristics, x X∈ , with the maximal 
predictive power across the entire set of all such models.  
<<Insert Table III here>> 
Table III lists the measures for each domain that maximized predictive power as well as 
their odds ratios from the logistic regression for participation. Measures of utilization, allergy 
diagnosis, and number of different primary care providers have a positive impact on the 
probability of participation;14
 While a behavioral model of the participation decision is interesting, the main 
importance of the participation regression is derivation of the propensity scores used to match 
participants and non-participants. Figure II shows that the propensity scores for the two groups 
had little overlap, which makes it more important to use full matching to make full use of the 
 the number of adults in the health plan has a negative impact. One 
characteristic of note is that the relationship between utilization and probability of participation 
is not linear in the variables; this highlights the importance of doing an exhaustive search over 
possible models.  
                                                 
14 Having an emergency room visit or urgent outpatient visit increased the probability of participation most likely 
because it served to highlight the negative outcomes associated with unmanaged asthma. The positive relationship 
between having controller medication and an allergy diagnosis and participation could be interpreted in two ways. 
Either those children with more severe asthma or comorbidities are more likely to participate, or that individuals 
with higher propensity to seek out health services are those who are more likely to participate. The number of 
primary care providers is probably capturing many factors that could affect continuity of care. 
 available data. Optimal full matching (Haviland et al., 2007)15 yielded 247 matched sets, 
matching 266 out of 270 people in the treatment group to 2,739 out of 2,742 in the control 
group.16
<<Insert Figure II here>> 
  The overlap in propensity scores improved significantly, as illustrated in the second 
frame of Figure II.  
We also conducted t-tests for each of the pre-treatment variables selected by the DSA 
algorithm. Because the relationship between participants and non-participants in each matched 
group is not one-to-one, we construct the sum of differences between each pair of individuals (i 
and j) within each group and weight this by the inverse of the number of matches within that 
group.    
( )1 ,Kk i j kx xx
K
=Σ −
=
 
 . 
The test statistics are reported in Table IV. With the exception of the number of control 
medications in the previous six months and number of adult family members with AAH 
insurance, the treatment and control groups do not differ significantly. Together, the overlap in 
the propensity scores of the two groups and the results of the t-tests suggest that optimal full 
matching has substantially reduced the bias in comparing outcomes across the two groups17
<<Insert Table IV here>> 
. 
 
                                                 
15 Using the optmatch package in R. 
16 The matched sets' quartile case : control ratios (.25, .5, .75, 1.0) are 1:13, 1:4, 1:1, 8:1; one matched set contained 
eight treated participants and one control.  Hence, the total number of matched sets (247) is less than the total of 
matched treated participants (266). 
17 In addition, we wanted to confirm that our analysis of program outcomes, described in the following section, was 
not sensitive to the choice of matching technique. Therefore, we tried several optimal matching combinations 
including 1:1, 1:4, 1:k without a penalty, and optimal matching with only propensity score distances and a caliper, 
and repeated our regressions of treatment outcomes each time. In each case, the regressions of treatment outcomes 
had odds ratios of similar magnitude and direction, regardless of the matching technique. Because optimal full 
matching is preferred on statistical grounds, we limit our presentation to only those results, but the results are 
qualitatively equivalent for all matching techniques.  
 5. Evaluation Results 
First, we use traditional bivariate analysis to measure the impact of the program on 
preventative care and treatment for exacerbations. Changes in preventative care are important 
intermediary steps to reduce the costly outcomes associated with certain consequences of asthma 
exacerbations (e.g., emergency room visits, hospitalization). Table V shows the results of five 
conditional logistic regressions for matched participant-control groups.18
<<Insert Table V here>> 
 
Compared to non-participants, participants were more likely to have engaged in two 
measures of risk-reducing behaviors: vaccinations for pulmonary illness (influenza or 
pneumonia) and using controller medications.19
                                                 
18 Note that conditional logistic regression for matched case-control groups is equivalent to fixed-effects logit for 
panel data; because of the health nature of the study, we will use the term most commonly used in biostatistics.  
 The odds ratios between participants and non-
participants are 2.95 for vaccinations (1.82 to 4.81, 95% CI) and 1.53 for controller medication 
(1.07 to 2.19, 95% CI). These are all promising indicators, and this increase in risk-reducing 
behaviors should translate into a reduction in adverse outcomes (asthma exacerbations). 
However, out of three indicators of treatment for asthma exacerbations in the six months 
following the program - the number of prescriptions for rescue medications, any nebulizer 
treatment, and any ED visit - only one is statistically different between the two groups at the 95% 
confidence level. The odds of a participant having a prescription filled for a rescue inhaler are 
1.49 times greater than for non-participants (1.07 to 2.07). It is unclear how to interpret the 
increase in prescriptions for rescue inhalers. Most children with asthma should have a rescue 
inhaler on hand in case of an emergency. OKA may have made more families aware of this fact 
19 We decided not to consider pulmonary testing because without a detailed chart review there is no way to 
accurately categorize this type of encounter as being due to an exacerbation or use as a preventative measure. 
 and encouraged them to have an adequate number of prescriptions20
Given the complex nature of asthma, the goal of a program such as OKA should not be 
simply to reduce consumption of specific health care services. More broadly, the goal should be 
to improve the overall state of a child's asthma. To reflect this priority, we created an indicator 
for change (or lack thereof) in asthma state after program participation. A child is considered to 
be in a negative asthma state if he or she has had a health care encounter to treat an asthma 
exacerbation or has had excessive use of rescue medication; otherwise he or she is in a stable 
asthma state. This definition is based on the Global Initiative on Asthma (GINA) and is similar 
to indices used in other studies of asthma exacerbations (see Price and Briggs, 2002 and Stempel 
et al., 2005). Since there are two possible states before and after participation, Hi  has four 
possible values, as illustrated in Figure III.
 - or OKA participants may 
have suffered a higher level of exacerbations, forcing them to refill their prescriptions more 
often.  
21
<<Insert Figure III here>> 
 Our approach is conservative, because a person is 
coded as being in a negative state if he or she has any encounter that indicates an asthma 
exacerbation. We use a strict definition for asthma control because we do not want to 
overestimate a treatment effect.  
We then estimated a conditional multinomial logit using Proc Glimmix where the outcome is the 
individual's score of the index. Table VI reports the probabilities of the four possible 
                                                 
20 For example, a child may need to have an inhaler at home and school. If prior to OKA the child did not have an 
inhaler at one of those places, or had an expired inhaler, then adding an inhaler after OKA is actually a risk-reducing 
behavior. 
21 The four possible values are strongly and logically associated with changes in direct health care costs discussed in 
the previous section. Recall that the mean decrease in costs for all OKA participants was $133. Participants who 
worsened had a mean increase of $166, while those who improved had a mean decrease of $377. Those who 
remained stable over both periods had a mean increase of $2, and those who remained in the negative state had a 
decrease of $65. Because these numbers are not relative to the control group, they do not reflect the impact of the 
program itself. However, they show the benefit to be gained by moving children from the negative to the stable 
state.  
 combinations of pre- and post-treatment states for the participants and non-participants. As 
previously discussed, asthma is a chronic disease with episodic symptoms. With perfect asthma 
control, an individual would stay in the stable state over time. In reality, asthma severity and risk 
reducing behaviors vary over time and individuals will move between stable and negative states. 
The statistics in Table VI illustrate how in the absence of an intervention a comparable group of 
children with asthma are distributed between stable and negative states over the two time periods 
relative to the intervention. The greatest share of non-participants (49%) were in a stable asthma 
state before intervention and stayed in that state after the intervention, and 20% of non-
participants worsened over the two periods. A smaller proportion of children who participated in 
the intervention started and remained in the stable states (30%), and 19% of participants 
worsened over the periods. There was no statistically significant difference in the conditional 
probability of worsening (moving into a negative state given a stable state initially) between the 
participants (0.39, 95% CI 0.28 to 0.52) and non-participants (0.29, 95% CI 0.27, 0.32). 
Likewise there is no statistically significant difference between participants and non-participants 
in the conditional probability of remaining stable given a stable initial state. A higher proportion 
of participants started in a negative state than non-participants, but again the difference is not 
statistically significant. However, there is a statistically significant difference in the conditional 
probability of improving given that the initial state was negative. The conditional probability of 
improving was 0.39 (0.3874, 0.3922) for participants and 0.49 (0.4867, 0.5021) for non-
participants.  
<<Insert Table VI here>> 
 
 6. Discussion 
 Our evaluation of Oakland Kicks Asthma demonstrates the challenges of validating the 
case management approach. We determined that program participants are more likely than non-
participants to use two types of recommended preventative health care - control medications and 
vaccines for respiratory infections - which could be due to greater awareness that asthma can be 
managed. However, we found no reduction in treatments for asthma exacerbations, and an 
increase in filling prescriptions for rescue medications. This increase may have been due to 
families updating expired prescriptions or obtaining new prescriptions to have rescue medication 
available at school, as suggested by discussions with OKA program managers, which would be a 
positive outcome, but this cannot be verified using the claims data available. A reduction in 
nebulizer treatments and ED visits, the other markers of asthma exacerbations, would be difficult 
to find in any case. First, these are uncommon events to begin with. Second, any long-term 
benefits of improved preventative care would only appear over a longer time frame.22
Alternatively a program could be effective for some segments of the target population but 
ineffective for others, making its impact statistically insignificant for the group of participants as 
a whole. Schuck and Zeckhauser (2006) characterize the inefficiencies (both economic and 
political) generated by not targeting social programs to those for whom the programs will do the 
most good.
 For these 
reasons, even a successful program could lead to an increase in utilization in the short term, 
before any long-term decrease in utilization becomes visible.  
23
                                                 
22 This limitation is evident in previous studies as well (see Evans et al., 1999; Harish et al., 2001;  Krieger et al., 
2005, and Morgan et al., 2004). 
 However, additional research can help us better understand these differences and 
thereby improve programs and outcomes.  
23 Schuck and Zeckhauser differentiate between those individuals who derive little benefit either relative to the 
resources consumed or relative to others in the program (bad best) from those individuals who actually impose 
  It is also plausible that the program did improve some outcomes, but that we were not 
able to measure those changes using our administrative data. The issue of measurement is 
complicated because the strength of the research design is the ability to compare the participants 
to non-participants who are similar in all other relevant dimensions. Typically these data are 
taken from administrative or insurance records. Measuring other changes (e.g., quality of life) 
would require surveying both participants and non-participants. 
Finally, the program may have faced structural challenges beyond its potential reach that 
prevented it from achieving its desired outcomes. One possible barrier is failure of physicians to 
follow best practice. Despite efforts to publicize and encourage physicians to implement existing 
asthma management guidelines, there is significant empirical evidence that physician compliance 
is low. A second potential barrier is household dysfunction that prevents effective management 
(Perry 2008).  
 
7. Conclusion 
The National Cooperative Inner City Asthma Study has given rise to a major wave of 
public investment in asthma intervention programs that use case management to affect household 
behaviors. We used a rigorous methodology to evaluate the Oakland Kicks Asthma program 
based on optimal matching that incorporated propensity score matching to construct a control 
group to compare to the group of program participants. In short, our evaluation finds that OKA 
has no significant effect on participants that distinguishes them from the control group, whether 
we look at utilization or transitions between negative and stable asthma states. This analysis 
raised a number of questions that it could not answer, because there are several competing 
                                                                                                                                                             
externalities on other participants (bad apples). We are primarily interested in avoiding bad bets because most of the 
asthma programs are focused on small groups or individuals. 
 explanations for not finding statistically significant changes in outcomes. Asthma programs 
funded by the CDC share a common approach to data collection and program evaluation – i.e., 
one that focuses on administrative measures rather than actual outcomes – therefore these 
uncertainties cannot be addressed even with the data aggregation over all of the various programs 
that are part of CAACP.  
To determine whether this type is asthma management intervention is effective, public 
health researchers need to be able to rule out several competing explanations for not finding 
statistically significant changes in outcomes: (1) the post-intervention time period may be too 
short to see changes; (2) utilization data miss relevant changes;  (3) even if the program has no 
significant impact on average, it may have a positive impact on a segment of participants; (4) 
structural barriers beyond the scope of the program may limit its impact; or (5) the program is 
not effective. Which of these possible explanations are appropriate requires a broad range of data 
about both participants and non-participants over an adequately long time-frame. In addition to 
improving the accuracy of the evaluation, these data would enable us to construct a richer model 
of the causal relationships between program attributes, participant behaviors, and outcomes. 
Then asthma intervention programs could be shaped to increase overall effectiveness and to 
target those participants who are most likely to benefit.  
We recommend three changes to how these national programs are implemented. First, 
resources must be invested in collecting long-run, detailed data on both participants and non-
participants thus improving the measurement of changes on the individual or household-level 
otherwise not captured in administrative data. Second, more research is needed to identify 
individual or household characteristics that increase the probability of a positive outcome due to 
the program. Third, the program can itself be targeted at those who are likely to derive a benefit 
 from participation. For example, one could design a two-stage program that provides a low-cost, 
group education program for any eligible household and then a second, more intensive and more 
costly, individualized intervention for the more committed families. This program design does 
reduce the total number of participants in the personalized program, but can increase the 
proportion that will see benefits and therefore increase the program's return on investment. Such 
a shift in the collection and usage of program data will both increase the public health benefits of 
the CDC's asthma programs and make it possible to shift resources toward those intervention 
models that are proven to succeed. 
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Figure II: Box plot of propensity score before and after matching  
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Figure III: Transitions between asthma states 
 
 Post intervention 
Prior intervention Stable state post Negative state post 
Stable state No change stable  (H=1) 
Reference group 
Worsened (H=2) 
Negative state Improved (H=3) No change negative (H=4) 
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Table I. Demographics of study participants (n=3,012) 
 
 Treatment group 
n (%) 
Control group 
n (%) 
Race/ethnicity   
Black 139 (51) 1,515 (55) 
Hispanic 96 (36) 736 (27) 
Asian 35 (13) 491 (18) 
Language   
English 155 (57) 1,778 (65) 
Asian group 25 (9) 371 (14) 
Spanish 88 (33) 593 (22) 
Missing/unknown 2 (1) 0 (0) 
Gender   
Male 147 (54) 1,446 (53) 
Female 123 (46) 1,296 (47) 
Age group at study start*   
2-11 103 (38) 1,234 (45) 
12-16 148 (55) 1,024 (37) 
17-22 19 (7) 484 (18) 
Allergy diagnosis   
     No 103 (38) 1,664 (61) 
     Yes 167 (62) 1,078 (39) 
   
N 270 2,742 
*The treatment group age range is 6-19, while the potential control group range is 2-22.  Participants in both groups 
were born between 1985 and 2000, but the control group had a greater age at the study start due to the random 
assignment of start dates.  Age was not selected by the DSA for being associated with OKA participation. 
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Table II: Health care use by treatment and control groups 1 year prior to enrollment 
HEDIS adapted variables 
 
Asthma-related health care Treatment group  
n (%) 
Control group 
n (%) 
Emergency department or 
urgent care visits  
  
0 210 (78) 2,568 (94) 
≥1 60 (22) 174 (6) 
Inpatient hospitalization    
0 255 (94) 2,709 (99) 
≥1 15 (6) 33 (1) 
Outpatient or MD office visits    
0 108 (40) 1,831 (67) 
≥1 162  (60) 911 (33) 
Flu or pneumonia vaccine   
0 226 (84) 2,509 (92) 
1 or 2 43 (16) 233 (8) 
Prednisone prescriptions    
0 218 (81) 2,545 (93) 
≥1 52 (19) 197 (7) 
Pulmonary tests   
0 196 (73) 2,464 (90) 
≥1 74 (27) 278 (10) 
Rescue prescriptions   
0 61 (23) 1,468 (54) 
1-8 175 (65) 1,208 (44) 
>8 34 (13) 66 (2) 
Control prescriptions   
0 104 (39) 1,997 (73) 
1-2 65 (24) 403 (15) 
>2 101 (37) 342 (12) 
   
N 270 2,742 
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Table III. Propensity score model (with OKA participation as the outcome) 
 
Pre-treatment characteristics Odds Ratio, Standard Error, [95% CI] 
Utilization and prescriptions  
# of control medications in the previous 6 months* 1.14, 0.04, [1.06, 1.22] 
Any control medication in the previous year* 1.55, 0.27, [1.10, 2.19] 
# of ED or urgent care visits for asthma in the previous 
6 months (squared) 4.51, 1.90, [1.97, 10.30] 
# of ED or urgent care visits for asthma in the previous 
6 months (cubed) 0.56, 0.12, [0.36, 0.86] 
# of outpatient visits for asthma in the previous year* 
(squared) 1.02, 0.01, [1.01, 1.03] 
Interaction with health care providers  
# different primary care physicians listed for a child in 
previous 6 months 5.89, 2.87, [2.27, 15.31] 
# different primary care physicians listed for a child in 
6 months (squared) 0.39, 0.17, [0.17, 0.90] 
Individual ever had an allergy diagnosis 1.75, 0.25, [1.32, 2.31] 
Socio-economic and demographic  
# adult family members with AAH health insurance 0.76, 0.07, [0.64, 0.91] 
% households in a study participant’s census tract with 
income between 25-50k** (cubed) 1.00, 0.00, [1.00, 1.00] 
 
*HEDIS defined variable 
**Rounded to the nearest hundredth 
 - 29 - 
Table IV.  T-test results of covariate balance based on weighted distribution among 
matched sets 
 
Variables Mean difference t-statistic 
# outpatient visits for asthma in the previous 
year* (squared) 
-0.45 -1.01 
# ER or urgent care visits for asthma in the 
previous 6 months (squared) 
0.00 -0.02 
# control medications in the previous 6 months* -0.13 -2.18 
# different primary care physicians listed for a 
child in previous 6 months 
0.02 1.17 
# adult family members with AAH health 
insurance 
-0.09 -1.83 
Allergy diagnosis (proportion) 0.02 0.77 
# different primary care physicians listed for a 
child in 6 months (squared) 
0.02 0.89 
% households in a study participant’s census 
tract with income between 25-50k (cubed) 
331.22 1.08 
Any control medication in the previous year* -0.04 -2.51 
# ER or urgent care visits for asthma in the 
previous 6 months (cubed) 
0.00 0.03 
*HEDIS defined variable 
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Table V. Bivariate odds ratios for outcomes from conditional logistic regression after OKA case management treatment 
 
Outcome Observations (n), 
matched sets 
OR Likelihood 
Ratio 
90% CI 95% CI Standard 
Error 
Preventative Care       
# of control medication 6 months 
post 
2359, 172 sets 1.53 -761.28 [1.13, 2.07] [1.07, 2.19] 0.28 
Any flu or pneumonia vaccine 1 
year post 
1507, 110 sets 2.95 -316.73 [1.97, 4.45] [1.82, 4.81] 0.73 
Treatment of exacerbation       
# of rescue medication 6 months 
post 
2511, 183 sets 1.49 -1154.9 [1.13, 1.96] [1.07, 2.07] 0.25 
Any nebulizer administration 6 
months post 
1462, 66 sets 1.93 -230.84 [1.09, 3.42] [0.98, 3.81] 0.67 
Any ED or urgent care center visit 
for asthma 6 months post 
1501, 70 sets 1.73 -259.98 [1.00, 3.00] [0.90, 3.33] 0.58 
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Table VI: Probabilities of asthma states 
 
Prior to intervention  Post intervention Participants  (95% CI) Non-participants (95% CI) 
Stable state Stable state 0.30  (0.18, 0.45) 0.49  (0.44, 0.54) 
Stable state  Negative state 0.19  (0.17, 0.20) 0.20  (0.20, 0.20)* 
Negative state  Negative state 0.31  (0.23, 0.38) 0.16  (0.13, 0.19) 
Negative state  Stable state 0.20  (0.15, 0.24) 0.15  (0.13, 0.18) 
 
* Due to rounding. 
 
These probabilities are derived from the conditional multinomial logit estimated using Proc 
Glimmix in SAS.
Appendix 
Table A1: Utilization measures 
 
Utilization measures ICD-9 procedure codes Binary 
Only 
Inpatient admissions 
(HEDIS defined*) 
99221-99223, 99231-99233, 99238-99239, 99251-99255, 99261-
99263, 99291-99292, 99356-99357 
 
Emergency Department  
(HEDIS defined) 
99281-99285, 99288  
Outpatient visits  
(HEDIS defined) 
99201-99205, 99211-99215, 99217-99220, 99241-99245, 99271-
99275 
 
Inpatient admission HEDIS codes plus 99235- 99236  
Treatment codes 90772, 90774, 90782, 94002-94004, 94640, 94642, 94644-94645, 
94660, 94662, 94665, 31500, 83735, 4025F, J1100, J1030, J7506, 
J7510, J7611,J7613-J7614, J7616, J7618- J7621, J7625- J7626, 
J7644, 
X5528, X5530, X5554 , X6004, X6008, X6014, X6036, X6038, 
X6328, X6580, J7510, E0570, E0570 
 
Inpatient treatment Any treatment code combined with inpatient hospital as place of 
service 
 
Emergency Department or 
Urgent Care visit 
HEDIS codes plus 90760, 96150-96151, 99062, 99064-99065, 
99236, , 99382-99384, 99394-99393, 450, Z7502, Z7610 
 
Emergency Department or 
Urgent Care treatment 
Any treatment code combined with emergency room or urgent 
care center as place of service 
 
Outpatient or physician’s 
office visit 
94664, 96150-96151, 99234, 99348, 99371-99374, 99382-99385, 
99392-99395 
 
Outpatient or physician’s 
office treatment 
Any treatment code combined with physician office or outpatient 
center as place of service 
 
Flu or pneumonia vaccine 90655-90660, 90669, 90724, 90732  
Nebulizer use 94640  
Pulmonary testing 92551-92552, 94010-94016, 94060, 94070, 94150, 94160, 94200, 
94375, 94620-94621, 94680, 94681, 94690, 94750, 94760-94762, 
94799, 95012, 95070, 95071, 82803, 82805, 31622, 31646, 3023F, 
3025F, 3027F, 3028F, 3035F, 3037F, 71010-71555, A4614, 
 
Home medical equipment 9944A, E1390, E0570, E0431, A9900, A7003, E0550, A7005, 
A7004 
X 
Allergy testing 94200, 94240, 95004, 95010, 95015, 95024, 95027, 95044, 95070, 
95075, 86001, 86003, 86005, 0168T 
X 
Allergy immunotherapy 95115, 95117, 95144-95149, 95165, 95170, 95199 X 
Other asthma education (not 
OKA) 
96150, 96151, 96155 X 
High severity visits to 
outpatient facility or 
doctor’s office 
99354, 99355, 99058, 99060, 99220, 99235, 99236 
 
 
Ambulance service X0036, A0800, 99289, X0030, A0434  
* Source: Healthcare Effectiveness Data and Information Set (HEDIS). 
Note: We felt that the HEDIS criteria were overly restrictive for our purposes, and we relaxed the HEDIS criteria to 
generate a second set of amended-HEDIS measures for ED visit, inpatient admission, and outpatient/doctor’s office 
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visit. Our adapted HEDIS definitions generally were more inclusive and contained more procedure and point of 
service codes than HEDIS. With the exception of home medical equipment, allergy testing, allergy immunology, 
and participation in asthma program other than OKA, variables were defined as both a binary measure of any 
encounter (0= no encounter, 1=any encounter) and a count of encounters. All variables are measured at 6 month and 
one year intervals. 
 
Table A2: Medication intensity scale 
 
Rescue 
prescriptions 1 
year prior to 
enrollment for 
eligible cases and 
controls 
OR for an ED 
visit 1 year after 
treatment 
SE 95% CI 
>0  1.18 0.20 [0.85, 1.64] 
>1 1.25 0.22 [0.88, 1.76] 
>2 1.17 0.24 [0.79, 1.75] 
>3 1.17 0.28 [0.74, 1.85] 
>4 1.19 0.32 [0.70, 2.01] 
>5 1.33 0.38 [0.76, 2.33] 
>6 1.71 0.51 [0.96, 3.06] 
>7 1.84 0.61 [0.96, 3.53] 
>8 2.64 0.90 [1.35, 5.13] 
>9 2.70 1.01 [1.29, 5.62] 
>10 2.97 1.18 [1.36, 6.50] 
>11 2.33 1.15 [0.89, 6.12] 
>12 2.71 1.35 [1.02, 7.19] 
>13 2.37 1.50 [0.69, 8.18] 
>14 2.88 1.85 [0.82, 10.14] 
>15 4.50 3.02 [1.20, 16.78] 
This is an application of Schatz et al.’s work (2006) to estimate categories of medication use where there is a change 
in the odds of an ED visit.  We created variables in Table II for rescue medication use (0, 1-8, and >8) where there 
were larger OR differences.  We wanted to differentiate between children who were properly using their rescue 
medication and those who were not.  We also included these categories in the DSA to model program participation. 
 
